Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A 30-year retrospective review of abnormalities among infants born to women using antiretrovirals shows low, consistent levels.
A 2018 report had suggested that HIV-positive women’s use of the drug at conception increased the risk of the rare birth defects.
The study randomized women starting HIV treatment during their third trimester to dolutegravir- or efavirenz-based antiretroviral regimens.
Researchers compared regimens prescribed to pregnant women in their second trimester.
Despite unanswered questions about PrEP’s safety and efficacy for pregnant women, they shouldn’t be denied Truvada for HIV prevention.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
The latest revision recognizes the importance of treatment as prevention.
This finding could potentially offer a way to blunt Zika’s devastating impact.
The World Health Organization recommends this highly effective antiretroviral for all population groups, including young women.
Changes include new information about risks associated with dolutegravir during pregnancy and removal of older drugs owing to toxicities.
Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.
Researchers argue that among children born to mothers with HIV, other factors such as the virus and substance use prompt such outcomes.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
A recent study compared birth outcomes among HIV-positive women exposed to various antiretroviral regimens.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.